In this week's episode we’ll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma.
Featured Articles:
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we’ll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma.
Featured Articles:
11,147 Listeners
140 Listeners
318 Listeners
499 Listeners
75 Listeners
26 Listeners
1,157 Listeners
2 Listeners
363 Listeners
373 Listeners
1 Listeners
48 Listeners
190 Listeners
30 Listeners
4 Listeners